Company / Return on Equity (ROE)
Larimar Therapeutics, Inc. Return on Equity (ROE) History
FY2016-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-55.8%
FY2019
5-year range
-55.8% / -34.9%
FY2016-FY2019
Trend
-17.3%
vs FY2018
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Larimar Therapeutics, Inc. reports negative total equity of -55.8% in FY2019. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-55.8% in FY2019 with a 3-year CAGR of -20.8%.
Declined from -43.9% to -55.8% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -20.8pp
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- Larimar Therapeutics, Inc.'s return on equity (roe) has declined for 3 consecutive years.
- In FY2019, return on equity (roe) decreased 17.3% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -4.64 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2019 | -55.8% | -17.3% |
| FY2018 | -47.5% | -8.2% |
| FY2017 | -43.9% | -25.8% |
| FY2016 | -34.9% | - |
| FY2015 | - | - |
| FY2014 | - | - |
As of FY2019 · SEC 10-K · Updated Jun 24, 2026